Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Trial of Recombinant RSV Vaccine (CHO cell) in Adults
CTR20254873Phase 2Active
- Sponsor
- Yidao Biotech
- Start
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant respiratory syncytial virus vaccine in respiratory syncytial virus disease (RSV), pulmonary infection, sponsored by Yidao Biotech. Started Jan 2026; status: active.
02
Drugs
recombinant respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on CTR20254873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254873.